2008 SAWC/WHS Attendee Registration

Characterization of the local wound environment following treatment of chronic leg ulcers with SIS wound matrix
34
Oral Abstracts (Session 3 of 5)

(Presentation 34.2)

Characterization of the local wound environment following treatment of chronic leg ulcers with SIS wound matrix

Jason P. Hodde, MS, ATC/L; Michael C. Hiles, PhD, Cook Biotech Incorporated, West Lafayette, Ind; Nicholas Sillings, BS; Dennis W. Metzger, PhD, Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY

The small intestinal submucosa wound matrix (SISWM)* has recently been shown to improve healing of chronic leg ulcers over standard of care in a randomized clinical trial enrolling 120 patients. In a related investigation, the authors tested the hypothesis that chronic venous ulcers responsive to treatment with this biomaterial would more closely mimic an acute wound state as opposed to unresponsive ulcers. In a series of 12 patients randomized to the SISWM group during the clinical trial, serum and wound exudate were collected at baseline and at weekly intervals for up to 12 weeks. All patients received weekly applications of SISWM, and 7 of the 12 patients eventually healed their wounds. Samples from all 12 patients were analyzed. Serum was examined for antibodies (total immunoglobulins) to the biomaterial, and wound exudates were analyzed for changes in matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-9, and MMP-12), proinflammatory cytokines (IL-1ß, TNF-alpha, IL-8), and transforming growth factor beta (TGF-ß1). A variety of Th1/Th2 cytokines were also assayed. Results showed significant decreases in MMP-1, MMP-2, MMP-3, and MMP-9, significant decreases in TNF-alpha and IL-8, and significant increases in TGF-ß1 over time in wounds responding to SISWM treatment versus wounds refractive to treatment as verified using t tests. None of the 12 patients formed a measurable serum antibody response to the SISWM. These data show that SISWM does not lead to immune system recognition when used to stimulate wound healing, and SISWM causes a shift to a more acute wound state for those wounds that do heal.

*Oasis Wound Matrix, Healthpoint, Ltd., Fort Worth Tex

References

Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41:856–862.


Back to Table of Contents